• Key Facts

• Farmers' suicides

• Rural distress

• Debt Trap

• Unemployment

• Migration

• GENDER

• Displacement

• Right to Food  

• Right to Work (MG-NREGA)

• Social Audit

• Right to Information

• Right to Education

• Forest and Tribal Rights

• Policy/ Action so far

• Poverty and inequality

• Hunger Overview

• Malnutrition

• HDI Overview

• Education  

• Public Health

• Mid Day Meal Scheme (MDMS)

• PDS/ Ration/ Food Security  

• MDGs

• Water and Sanitation

• Impact on Agriculture

• Time Bomb Ticking

• Social Justice

• Access to Justice

• Human Rights

• Corruption

• General Insecurity

• Disaster & Relief

Himachal Pradesh government flunks forest rights’ subject-Manshi Asher

-Tehelka Close to 30 percent of forests have been converted to Chir Pine monocultures displacing grazing rights of several communities like the Gaddis and Gujjars. There is no quantitative assessement of the impact of loss on people's lives The Scheduled Tribes and Other Traditional Forest Dwellers Act, or Recognition of Forest Rights Act - commonly known as the Forest Rights Act (FRA)...

Mandatory CSR in India: A Bad Proposal-Aneel Karnani

-Stanford Social Innovation Review Looked at from the perspective of the political right, and the left, and the center, the proposed law making CSR mandatory is a really bad idea. Companies all over the world are under increasing pressure to demonstrate that they are responsible citizens, with about 70 percent of large companies in Europe and the Americas reporting on their...

Ranbaxy's dark chapter-Bhupesh Bhandari

-The Business Standard Why have Indian authorities woken up to the Ranbaxy case only now? The matter had been simmering for several years The Ranbaxy affair is one of the darkest chapters of India's business history. The company has admitted it fudged data so that it could launch its products in the United States. It has now paid $500 million as a...

Ranbaxy case may take a toll on other Indian drug makers

-The Business Standard The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to...

New bulk drug export norms to comply with EU standards

-The Hindu The Commerce and Industry Ministry, on Thursday, issued new guidelines for pharmaceutical makers to comply with the European Union (EU) Good Manufacturing Practice (GMP) standards. In a statement issued here, the Ministry says such a move will give a boost to pharma exports from India. "India has demonstrated its keenness to meet international requirements for exports of pharmaceutical products yet...